Praxis Precision posts bigger Q4 loss as R&D costs grow

Praxis Precision Medicines

19/02/2026 12:40

Overview

CNS biopharmaceutical firm reported wider Q4 net loss of $88.9 mln, with increased R&D expenses

Praxis submitted NDAs for ulixacaltamide and relutrigine to the FDA

Company raised $621 mln in January 2026 public offering, funding operations into 2028

Outlook

Praxis expects topline results for vormatrigine in Q2 2026

Company anticipates NDA submissions for vormatrigine and elsunersen by 2028

Praxis expects cash runway to fund operations into 2028

Result Drivers

NDA SUBMISSIONS - Praxis submitted NDAs for ulixacaltamide and relutrigine, positioning for commercial transition

COMMERCIAL PREPARATIONS - Co is preparing for the commercial launch of ulixacaltamide and relutrigine, including scaling its commercial organization

INCREASED R&D EXPENSES - Higher R&D costs driven by investments in Cerebrum and Solidus platforms

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$3.50
Q4 Net Income
-$88.91 mln
Q4 Operating Expenses
$97.04 mln
Q4 Operating Income
-$97.04 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Praxis Precision Medicines Inc is $505.00, about 53.5% above its February 18 closing price of $328.93

Press Release: ID:nGNX1CpNyj

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)